Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)

Cash, cash equivalents and short-term investments at quarter end were $603M vs. $706M at previous quarter end. “We are excited to report that the advances and strong momentum Viking created in 2025 have carried forward through Q1 of 2026,” stated CEO Brian Lian. “Looking ahead, we continue to execute the Phase 3 clinical development program for our lead obesity program VK2735. Our VANQUISH Phase 3 studies of the subcutaneous formulation are fully enrolled, and our planned Phase 3 studies with the oral tablet formulation are expected to begin later this year, marking a rapid pace of development for this important program. Our goal with these studies is to introduce the industry’s first oral and subcutaneous dual GLP-1 and GIP co-agonist molecule for the treatment of obesity…Concurrent with our Phase 3 activities, our novel maintenance dosing trial continues, and we expect to generate data from this study in the third quarter. With our earlier-stage pipeline, our amylin agonist continues to advance, and we expect to initiate a Phase 1 trial for the lead molecule VK3019 later this quarter. Operationally, as VK2735 continues to advance, our organization continues to evolve, as well…”